logo

Apyx Medical Corporation (APYX)



Trade APYX now with
  Date
  Headline
2/1/2023 7:45:49 AM Apyx Medical Submits 510(k) Premarket Notification For Renuvion APR Handpiece To FDA
1/10/2023 7:05:30 AM Apyx Medical Corp. Reports Q4 Preliminary Total Revenue Of $12.1 Mln To $12.5 Mln
11/10/2022 7:07:42 AM Apyx Medical Q3 Net Loss $5.8 Mln Vs Loss $4.2 Mln Prior Year
7/18/2022 7:36:23 AM Apyx Medical Receives FDA 510(k) Clearance For Use Of Renuvion To Improve Appearance Of Loose Skin
6/28/2022 7:37:37 AM Apyx Medical Device Used By Physicians In US Now Available To Patients For Nonsurgical Facial Renewal
5/26/2022 8:37:04 AM Apyx Medical Receives FDA 510 Clearance For Use Of Renuvion Cosmetic Technology In Dermal Resurfacing Procedures
5/12/2022 7:13:40 AM Apyx Medical Q1 Net Loss Attributable To Stockholders $5.9 Mln; Adjusted EBITDA Loss To Report Nwgative Of $4.0 Mln
4/4/2022 7:07:24 AM Apyx Medical Announces FDA 510(k) Submission With Clinical Study Support For Use Of Renuvion APR Handpiece
3/17/2022 7:07:59 AM Apyx Medical Q4 Ne Loss $2.0 Mln Vs. Net Loss $1.5 Mln Last Year
1/10/2022 7:37:02 AM Apyx Medical Sees Q4 Total Revenue In A Range Of $16.3 Mln To $16.8 Mln
11/11/2021 4:17:45 PM Apyx Medical Q3 Loss/share $0.12 Vs. Loss $0.11 Year Ago
8/30/2021 7:35:16 AM Apyx Medical Appoints Wendy Levine To Board
8/12/2021 7:11:19 AM Apyx Medical Q2 Net Loss Attributable To Stockholders $4.0 Mln Vs Net Loss $4.7 Mln Last Year
6/1/2021 7:34:00 AM Apyx Medical Announces FDA 510(k) Submission For Use Of Renuvion In Dermal Resurfacing Procedures
5/12/2021 7:10:50 AM Apyx Medical Q1 Net Loss $4.9 Mln Vs. Net Loss $2.0 Mln Last Year
3/31/2021 7:17:51 AM Apyx Medical Q4 Loss Per Share $0.04 Vs Loss $0.16 Last Year